



**P.17019/01/2019-PvPI**  
**Indian Pharmacopoeia Commission**  
**National Coordination Centre-Pharmacovigilance Programme of India**  
**(Ministry of Health & Family Welfare, Govt. of India)**

**Sector-23, Rajnagar,**  
**Ghaziabad-201002, U.P**  
**Dated: September 05, 2019**

**Monthly Drugs Safety Alerts**

The preliminary analysis of Adverse Drugs Reactions from the PvPI database reveals that the following drugs are associated with the risks as given below.

**Table**

<b>Sl. No</b>	<b>Suspected Drugs</b>	<b>Indication</b>	<b>Adverse Drugs Reactions</b>
1	Teneligliptin	For the treatment of type-2 Diabetes Mellitus as a monotherapy adjunct to diet and exercise.	Arthralgia
2	Atorvastatin	As an adjunct to diet to reduce elevated total cholesterol & triglyceride level in patients with primary hypercholesterolemia & mixed dysbetalipoproteinemia (Type IIa & IIb)	Vit-D deficiency

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADRs associated with the use of above drugs. If such reactions are encountered, please report to the NCC-PvPI, IPC either by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI **Helpline No. 1800-180-3024**.